{"title":"China's legal framework for pharmaceutical products: challenges and opportunities for EU companies","authors":"Pamela Lattanzi, Federica Monti, Zhao Xu","doi":"10.1504/IJHTM.2017.10006645","DOIUrl":null,"url":null,"abstract":"It is unanimously recognised in the literature that although the Chinese pharmaceutical market offers huge opportunities to European industry, it poses several challenges regarding compliance with the laws governing this sector. Because of the different legal traditions, a peculiar public health history and culture, and a different system of healthcare, EU companies have faced many barriers in accessing the Chinese pharmaceutical market over the years. In order to provide a better understanding of the China's regulatory landscape and its emerging trends, the article focuses on three critical legal topics, which are relevant for the business of EU pharmaceutical companies in the Chinese market: drug registration, drug distribution system, and IP rights protection.","PeriodicalId":51933,"journal":{"name":"International Journal of Healthcare Technology and Management","volume":"16 1","pages":"128-154"},"PeriodicalIF":0.4000,"publicationDate":"2017-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Healthcare Technology and Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1504/IJHTM.2017.10006645","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 5
Abstract
It is unanimously recognised in the literature that although the Chinese pharmaceutical market offers huge opportunities to European industry, it poses several challenges regarding compliance with the laws governing this sector. Because of the different legal traditions, a peculiar public health history and culture, and a different system of healthcare, EU companies have faced many barriers in accessing the Chinese pharmaceutical market over the years. In order to provide a better understanding of the China's regulatory landscape and its emerging trends, the article focuses on three critical legal topics, which are relevant for the business of EU pharmaceutical companies in the Chinese market: drug registration, drug distribution system, and IP rights protection.
期刊介绍：
IJHTM is a new series emerging from the International Journal of Technology Management. It provides an international forum and refereed authoritative sources of information in the fields of management, economics and the management of technology in healthcare.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
